Drugs / AKB-9090
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07429006 | Mar → Oct 2026 expected | — | Akebia Therapeutics | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-13 | Akebia Therapeutics | Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 akebia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AKB-9090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07429006 ↗ |
| Route | Intravenous | “AKB-9090 will be administered intravenously” NCT07429006 ↗ |